User:Tomtillet/sandbox

Revance Therapeutics, Inc. is an American pharmaceutical company. Revance is headquartered in Nashville, Tennessee. The company was founded on August 10, 1999, and is listed on the Nasdaq stock exchange.

Company overview
Revance is a one of a handful of companies in the global facial injectibles market which is projected to reach $9.07 billion by 2028.

Products and services
Revance has two business units: aesthetics and therapeutics. The primary product for both units is DaxibotulinumtoxinA, or DAXI for short. DAXI is a botulinum toxin designed to block nerve signals leading to muscles. Typically, botulinum toxins are delivered via injection, and would be used for treating muscle spasms and for cosmetic treatment of wrinkles. According to company officials, Revance's DAXI product could be applied through a topical gel.

Revance's aesthetics unit is using DAXI as a facial treatment for wrinkles. Revance's therapeutics unit is examining DAXI for use in several areas, including treatment of cervical dystonia; adult upper limb spasticity, a neurologic condition that affects movement in the arms or hands and occurs most commonly after a stroke or brain injury; plantar fasciitis; and migraine headaches.

Partnerships
Revance has created several partnerships, including a distribution agreement to market dermal fillers made by Teoxane Laboratories, a Swiss company, in the United States. Revance is also partnering with Viatris, Inc., allowing Revance to compete in the short-acting neuromodulator market. Finally, Revance has contracted with Fosun Pharma to market Revance offerings in China.

U.S. offices
Revance is headquartered in Nashville Tennessee, and has three corporate offices in California, including in Irvine, where the company performs its commercialization; Pleasanton, where it works on technology; and Newark, which it conducts manufacturing and research and development.

Stock market
Revance is traded on the Nasdaq exchange under the symbol RVNC. Its stock price has fluctuated as it awaits approval by the U.S. Food and Drug Administration. In October 2021, the FDA denied Revance's application due to manufacturing issues, and Revance has renewed its talks with the regulator to seek approval for treatment of frown lines.